Related Experiment Video
Updated: Jun 29, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Pharmacokinetic Prediction of Repurposed Drugs for PDAC Using Artificial Intelligence
Pragya Pragya1, Shashwat Singh1, Bhuvaneshwari Balasubramaniam2
1Computational Neuroscience and Biology Lab, School of Biomedical Engineering, Indian Institute of Technology (BHU) Varanasi, Varanasi 221005, India.
None:
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer that accounts for 95% of cases of pancreatic cancer. It develops in the ducts and shows high drug resistance. In this study, we proposed a framework to predict the pharmacokinetic (PK) properties of repurposed drugs for PDAC using artificial intelligence (AI). Initially, the molecular features of repurposable drugs for PDAC were generated through three types of molecular descriptors: RDKit, MACCS, and ECFP6. Then, the corresponding absorption (Caco-2 cell permeability), distribution (volume of distribution), metabolism (CYP2C9 inhibitor), excretion (half-life), and toxicity (hERG) properties of the drugs were obtained from ADMETlab 3.0. We constructed AI models such as multilayer perceptron (MLP), random forest (RF), extreme gradient boosting (XGB), and one-dimensional convolutional neural network with different combinations of molecular descriptors as the input. The performance of the models was evaluated on an open-access data set, Therapeutics Data Commons (TDC), and using evaluation metrics. Our results show that the highest-performing molecular descriptor combination and AI models vary with respect to the PK properties. Models on the PDAC data set achieved a mean absolute error (MAE) of 0.18 (MACCS+XGB), Spearman correlation (SC) of 0.39 (MACCS+RF), area under the precision-recall curve (AUPRC) of 59.44% (MACCS+ECFP6+MLP), SC of 0.68 (RDKit+ECFP6+XGB), and SC of 0.77 (MACCS+RF) for absorption, distribution, metabolism, excretion, and toxicity, respectively. The corresponding values on the TDC data set are an MAE of 0.26 (RDKit+MACCS+MLP), an SC of 0.62 (MACCS+ECFP6+MLP), an AUPRC of 67.11% (RDKit+MACCS+ECFP6+1D-CNN), an SC of 0.39 (MACCS+RF), and an SC of 0.92 (RDKit+XGB/RDKit+MACCS+RF). These results suggest that combining molecular fingerprints with AI can effectively model PK properties. This approach supports the use of AI for accelerating drug repurposing, especially for disease conditions.
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacodynamic Models: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

